Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E18.59 EPS (ttm)4.21 Insider Own0.54% Shs Outstand1.27B Perf Week7.36%
Market Cap99.09B Forward P/E12.23 EPS next Y6.40 Insider Trans-2.18% Shs Float1.25B Perf Month2.73%
Income5.39B PEG72.32 EPS next Q1.56 Inst Own84.80% Short Float2.12% Perf Quarter20.19%
Sales22.45B P/S4.41 EPS this Y1.10% Inst Trans0.03% Short Ratio1.34 Perf Half Y25.68%
Book/sh17.78 P/B4.40 EPS next Y0.52% ROA8.70% Target Price74.71 Perf Year17.01%
Cash/sh19.22 P/C4.07 EPS next 5Y0.26% ROE24.60% 52W Range60.89 - 85.97 Perf YTD20.36%
Dividend2.72 P/FCF19.44 EPS past 5Y-10.50% ROI9.50% 52W High-9.03% Beta0.67
Dividend %3.48% Quick Ratio3.00 Sales past 5Y-2.00% Gross Margin79.20% 52W Low28.44% ATR4.96
Employees11800 Current Ratio3.10 Sales Q/Q1.40% Oper. Margin19.10% RSI (14)57.37 Volatility4.56% 7.28%
OptionableYes Debt/Eq1.09 EPS Q/Q89766.70% Profit Margin24.00% Rel Volume0.96 Prev Close76.98
ShortableYes LT Debt/Eq0.98 EarningsMay 05 AMC Payout59.50% Avg Volume19.87M Price78.21
Recom2.50 SMA205.91% SMA5010.75% SMA20017.35% Volume19,104,843 Change1.60%
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-20-20Upgrade Piper Sandler Neutral → Overweight $70 → $90
Mar-18-20Upgrade DZ Bank Hold → Buy $80
Mar-09-20Downgrade RBC Capital Mkts Top Pick → Outperform $86
Feb-27-20Initiated Barclays Underweight $62
Feb-06-20Downgrade Bernstein Outperform → Mkt Perform $78 → $70
Feb-05-20Downgrade Raymond James Strong Buy → Outperform $81 → $80
Jan-21-20Downgrade Guggenheim Buy → Neutral
Dec-13-19Downgrade Credit Suisse Neutral → Underperform $67 → $63
Nov-12-19Initiated SunTrust Hold $70
Oct-25-19Downgrade Maxim Group Buy → Hold
Oct-17-19Resumed BofA/Merrill Neutral $70
Jul-29-19Upgrade RBC Capital Mkts Outperform → Top Pick $91
Jul-15-19Upgrade Wells Fargo Market Perform → Outperform $68 → $88
May-28-19Downgrade Goldman Neutral → Sell
May-23-19Upgrade Citigroup Neutral → Buy
May-21-19Initiated Credit Suisse Neutral $70
Apr-26-19Initiated Bernstein Outperform $82
Apr-10-19Upgrade UBS Neutral → Buy $75 → $77
Feb-12-19Downgrade Wells Fargo Outperform → Market Perform $95 → $68
Apr-05-20 04:03PM  Gilead To Donate 1.5M Doses Of Experimental Coronavirus Treatment: 'The Right Thing To Do' Benzinga
10:23AM  These 19 companies are working on coronavirus treatments or vaccines heres where things stand MarketWatch
10:22AM  Theres scant evidence so far for chloroquine as a COVID-19 drug but theres already a shortage MarketWatch
07:48AM  Spain Deaths Slow; Singapore Quarantines Dorms: Virus Update Bloomberg
06:58AM  3 Coronavirus Stocks That Could Lead the Market to Recovery TipRanks
Apr-03-20 06:34PM  7 Biotech Stocks to Buy for a Post-Pandemic World Barrons.com
04:14PM  Covid Report: Gilead Pops After EMA Recommends Its Coronavirus Drug Investor's Business Daily
02:59PM  Gilead Sciences Coronavirus Treatment Has Big-Time Potential InvestorPlace
10:37AM  The Best and Worst-Performing S&P 500 Stocks of the 1st Quarter GuruFocus.com
09:48AM  Incyte to Evaluate Lead Drug Jakafi for COVID-19 Infection Zacks
09:18AM  EMA recommends compassionate use of Gilead's remdesivir for COVID-19 Reuters
08:53AM  Swiss ease access to COVID-19 treatments with exceptional decree Reuters
Apr-02-20 04:19PM  Recovering From the Coma GuruFocus.com +6.16%
10:15AM  Healthcare stocks show their defensive allure in ailing market Reuters
08:30AM  Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma Business Wire
Apr-01-20 04:18PM  Covid Report: Testing News Sends One Biotech Flying As Another Dives Investor's Business Daily
02:02PM  How to Trade Gilead Sciences as It Works on a Coronavirus Treatment TheStreet.com
09:42AM  Tiny Bay Area company aims to win coronavirus vaccine race with a tablet American City Business Journals
Mar-31-20 08:43PM  These 30 S&P 500 stocks actually rose during the disastrous first quarter MarketWatch
05:45PM  Gilead Sciences (GILD) Stock Moves -1.54%: What You Should Know Zacks
02:18PM  8 Experimental Coronavirus Treatments to Watch Barrons.com
10:51AM  Gilead Expands Access to Experimental Coronavirus Treatment Zacks
09:00AM  Demand Rises For Gilead's Coronavirus Drug But Is GILD Stock A Buy? Investor's Business Daily
Mar-30-20 06:00PM  What Does A Double Bottom Base Look Like? This Top Biotech Stock Formed A Great One Investor's Business Daily
04:27PM  Covid Report: Gilead Nears Coronavirus Data In 'Weeks'; J&J Bullish On Vaccine Investor's Business Daily
10:25AM  Gilead CEO: 'Working at unprecedented speed' to snuff out COVID-19 American City Business Journals
08:30AM  Gilead Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer Business Wire
Mar-29-20 11:36AM  Gilead Sciences Expects Coronavirus Drug Data in Coming Weeks, Expands Access SmarterAnalyst
07:42AM  2 Biotech Stocks in the Hunt for New Coronavirus Drugs; Oppenheimer Weighs In TipRanks
Mar-27-20 01:20PM  Coronavirus Drugs Already in the Pipeline Kiplinger
12:59PM  The Easy Gains May Be Over for American Airlines Stock InvestorPlace
11:28AM  Read the Label Before Buying AIM Stock InvestorPlace
11:00AM  Big Pharma and Biotech Need to Do More in the Fight Against Covid-19 Barrons.com
10:27AM  Coronavirus Means Fewer Stock Buybacks, Analyst Says. It Could Shake Up Biopharma. Barrons.com
10:04AM  UC Davis conducting clinical trials of two drugs to treat COVID-19 American City Business Journals
09:21AM  The Zacks Analyst Blog Highlights: Moderna and Gilead Sciences Zacks
06:40AM  In the Coronavirus Vaccine Race, AIM Stock Isnt a Likely Winner InvestorPlace
06:40AM  Use of experimental COVID-19 drug grows in Boston: Theres nothing else American City Business Journals
Mar-26-20 08:17PM  10 Health and Pharmaceutical Companies Fighting the Coronavirus Kiplinger +6.03%
06:16PM  Gilead Asks FDA to Withdraw Orphan Drug Tag for Remdesivir Zacks
04:38PM  How to Survive the Economic Fallout from COVID-19 Kiplinger
10:16AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals Zacks
07:08AM  Duke University Hospital to test potential COVID-19 treatment on patients American City Business Journals
Mar-25-20 06:57PM  J&J's Chief Scientific Officer predicts vaccinations against coronavirus within 12 months Yahoo Finance -5.81%
04:51PM  Drugmaker Gilead backpedals on specialty status for COVID-19 drug MarketWatch
04:15PM  Covid Report: Gilead Asks FDA To Rescind Key Status For Coronavirus Drug Investor's Business Daily
02:40PM  Gilead pulls back 'orphan drug' request for experimental COVID drug American City Business Journals
01:47PM  Gilead asks FDA to revoke orphan drug status for potential coronavirus drug Reuters
12:33PM  Top 5 Drug Stocks To Stop The Coronavirus Pandemic Zacks
10:34AM  Biotech Stock Roundup: HOTH & IMV to Develop Coronavirus Vaccines, & More Zacks
10:28AM  S.F. biotech races potential COVID-19 drug toward clinical trial American City Business Journals
07:00AM  Hoarding Chloroquine Won't Cure Coronavirus Bloomberg
03:08AM  Gilead asks to rescind special status for potential coronavirus drug Financial Times
Mar-24-20 05:57PM  US Indexes Regain Some Ground Tuesday GuruFocus.com
04:23PM  Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch
10:19AM  3 Biotech Stocks Fighting the Coronavirus; Heres What to Expect TipRanks
09:37AM  Gilead Sciences Jumps Higher After FDA Gives Coronavirus Treatment 'Orphan Drug' Status TheStreet.com
04:02AM  Stocks - Chevron, Intel Surge in Premarket on Cash Conservation Packages Investing.com
03:06AM  Singapore scientists study genes to fast-track coronavirus vaccine Reuters
Mar-23-20 09:59PM  Gilead criticised over orphan status for potential virus treatment Financial Times
05:44PM  Gilead's potential coronavirus treatment gets FDA's orphan drug label Reuters
04:25PM  UC Irvine researchers to test former Ebola drug in coronavirus clinical trial American City Business Journals
04:16PM  Covid Report: Overtaxed, Gilead Suspends Access To Coronavirus Drug Investor's Business Daily
03:53PM  Coronavirus Updates: What's the Latest? A Timeline of Recent Events TheStreet.com
12:02PM  Gilead Sciences, 'flooded' by demand for remdesivir, halts compassionate use MarketWatch
09:47AM  2 giant biotechs have 'remarkable' meetings with Gov. Newsom then one shifts to expanded access for potential COVID drug American City Business Journals
Mar-22-20 06:33PM  Gilead Stops Accepting Emergency Applications for Covid-19 Drug Barrons.com
04:45PM  Gilead shifting access to potential coronavirus drug to clinical trials Reuters
10:13AM  Trump makes the case for chloroquine as a COVID-19 treatment, though it has not been approved by the FDA for this illness MarketWatch
Mar-20-20 02:52PM  Why BofA Has Low Expectations For Gilead's Remdesivir As Potential Coronavirus Treatment Benzinga -6.73%
01:31PM  Gileads Coronavirus Vaccine Candidate Shows Promise, Says Cowen TipRanks
12:01PM  Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group Zacks
Mar-19-20 06:40PM  The 12 Best Low-Volatility Stocks of the Market Crash Kiplinger
05:45PM  Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know Zacks
04:51PM  Covid Report: Gilead Sinks After Trump Backing For Coronavirus Drug Investor's Business Daily
04:18PM  Coronavirus update: US cases top 10K as testing ramps up; Italian deaths vault above China's Yahoo Finance
03:16PM  Options Pop on Outperforming Gilead Stock After Trump Touts Treatment Schaeffer's Investment Research
03:02PM  President Trump Praises Antiviral Treatments in FDA News Conference Barrons.com
02:58PM  Italy Deaths Top China; Trump Touts Malaria Drug: Virus Update Bloomberg
02:56PM  Potential coronavirus treatment touted by Trump already in shortage -pharmacists Reuters
02:40PM  U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection Business Wire
01:07PM  Bayer donates 3 mln malaria tablets to U.S. for potential use against coronavirus Reuters
01:06PM  Trump: FDA Clears 2 Antivirals to Battle Coronavirus Symptoms TheStreet.com
11:33AM  Kyle Bass: You Can Be a Value Investor Again GuruFocus.com
07:50AM  Analyst Says Gilead's Remdesivir Could Be Approved 'Within Months' For COVID-19 Treatment Benzinga
07:00AM  Two generic drugs being tested in U.S. in race to find coronavirus treatments Reuters
06:00AM  A Watch List to Nibble On MoneyShow
Mar-18-20 04:24PM  Pharmaceutical Companies Gain in the Fight Against Covid-19 GuruFocus.com +6.58%
08:45AM  Think twice before investing in biotech companies working on coronavirus treatments the odds of picking a winner are low MarketWatch
08:28AM  Heres one analysts take on the coronavirus drugs for today and the future MarketWatch
Mar-17-20 04:34PM  Top Stocks for April 2020 Investopedia +8.16%
02:57PM  Top Health Care Stocks for April 2020 Investopedia
02:26PM  Regenerons CEO Says We Could Have a Covid-19 Treatment Quickly Barrons.com
02:04PM  Top Pharmaceutical Stocks for Q2 2020 Investopedia
11:46AM  10 Quality Stocks That Are Priced at a Steal Right Now Barrons.com
11:15AM  A Coronavirus Treatment Worth Watching Bloomberg
06:00AM  5 Biotechs in Search of a Coronavirus Vaccine MoneyShow
Mar-16-20 06:30PM  Gilead Up as Remdesivir Shows Promise in Treating Coronavirus Zacks
12:09AM  'This can happen to anyone': How this cell therapy pioneer, diagnosed with the coronavirus, wants to destigmatize COVID-19 American City Business Journals
Mar-13-20 06:59PM  Coronavirus and Pharma: Will Emergency Approvals Help or Hurt? GuruFocus.com
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; and Zydelig, a kinase inhibitor for the treatment of patients with relapsed chronic lymphocytic leukemia, relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma. In addition, the company offers Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. Further, it provides its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Additionally, the company focuses to develop product for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. It markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with The Rockefeller University; Novartis AG; Lyndra Therapeutics, Inc.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Eisai Co., Ltd.; Galapagos NV; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; and Kiniksa Pharmaceuticals, Ltd. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 02Sale70.8810,441740,01414,644Mar 03 07:40 PM
Lofton Kevin EDirectorFeb 24Option Exercise19.6321,720426,36486,579Feb 25 05:13 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Option Exercise40.5615,000608,40032,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Sale66.8515,0001,002,80917,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Sale64.9110,000649,06217,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Sale63.8510,000638,50017,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM
WOLD OLSEN PERDirectorAug 28Option Exercise23.764,908116,590102,762Aug 29 04:42 PM
WOLD OLSEN PERDirectorAug 28Sale63.914,908313,67197,854Aug 29 04:42 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecAug 19Sale64.3560839,12327,198Aug 20 03:13 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Option Exercise24.917,200179,31634,398Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJul 23Sale65.077,200468,50427,198Jul 25 06:37 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecJun 18Sale68.755,816399,85027,198Jun 20 04:52 PM
Whitley Richard JamesDirectorMay 01Option Exercise22.029,534209,89134,669May 02 06:48 PM
Cogan John FrancisDirectorMay 01Option Exercise22.022,86863,13957,728May 02 06:45 PM
Whitley Richard JamesDirectorMay 01Sale65.029,534619,93425,135May 02 06:48 PM
Cogan John FrancisDirectorMay 01Sale64.892,868186,11654,860May 02 06:45 PM
Cogan John FrancisDirectorApr 24Option Exercise22.022,70059,44157,560Apr 25 06:48 PM
Lofton Kevin EDirectorApr 24Option Exercise24.9113,208328,94543,332Apr 25 06:51 PM
Cogan John FrancisDirectorApr 24Sale62.612,700169,05454,860Apr 25 06:48 PM
Cogan John FrancisDirectorApr 17Option Exercise22.022,70059,44157,560Apr 18 07:04 PM
Cogan John FrancisDirectorApr 17Sale64.232,700173,42454,860Apr 18 07:04 PM
Cogan John FrancisDirectorApr 10Option Exercise22.022,70059,44157,560Apr 12 06:28 PM
Cogan John FrancisDirectorApr 10Sale67.232,700181,52154,860Apr 12 06:28 PM